We're not curing as many cancers as we could. Think big and be courageous.
When one of Australia's foremost cancer researchers received a diagnosis that typically ends lives within months, the boundary between healer and patient dissolved — and in that dissolution, something unexpected emerged. Richard Scolyer, a melanoma specialist struck by glioblastoma while hiking in Poland, became the subject of his own field's boldest experiment: applying immunotherapy techniques refined for skin cancer to a brain tumor long considered beyond their reach. Early results suggest the blood-brain barrier, medicine's long-assumed wall, may be more permeable than believed — a finding that could quietly reshape how the world approaches one of its most feared diagnoses.
- A sudden seizure in Poland ended a hiking trip and began a race against a cancer that kills most patients within six to nine months.
- Scolyer's colleague and co-director Georgina Long turned grief into urgency, only to find the landscape of available glioblastoma trials nearly empty.
- With no established path forward, the team made the audacious decision to treat a brain tumor the way they had learned to treat melanoma — a move that drew skepticism from parts of the oncology community.
- Ten weeks after treatment began, lab results showed a tenfold increase in immune cells attacking the tumor, suggesting the drugs had crossed the blood-brain barrier everyone assumed would stop them.
- The treatment remains unavailable to other patients, and whether the science translates to Scolyer's own survival is still unknown — but pharmaceutical companies are beginning to take notice.
Richard Scolyer was at the peak of his career — competing internationally, leading melanoma research in Australia — when a seizure during a hiking trip in Poland changed everything. The diagnosis was glioblastoma, a brain cancer considered incurable, with a typical prognosis of six to nine months.
The first call from that Polish hospital went to Georgina Long, Scolyer's colleague and co-medical director at Melanoma Institute Australia. Her grief was immediate and physical — but it became the engine of action. When she searched for clinical trials, she found almost nothing. Glioblastoma had been largely abandoned by the immunotherapy revolution that had transformed melanoma treatment.
So Long and Scolyer decided to cross that boundary themselves. They would treat his brain cancer the way they had learned to treat skin cancer — with drugs designed to activate the immune system against the tumor, combined with a personalized vaccine built from the genetic sequencing of his specific cancer. Scolyer, as both patient and researcher, understood the risks and consented fully. Not everyone in the oncology world approved, and he and his wife spent hours writing letters to explain and defend the approach.
The early results were striking. Tissue taken during surgery twelve days after treatment began showed a tenfold increase in immune cells inside the tumor — cells activated against the cancer and bound to the drug. More significantly, it demonstrated that the blood-brain barrier, long thought to block immunotherapy from reaching brain tumors, was not the absolute obstacle medicine had assumed. In ten weeks, they had produced findings that would normally require years of research.
Both Scolyer and Long were measured in how they described this. One patient. Early data. No certainty about what it means for his prognosis. The treatment is not yet available to others, and pharmaceutical investment in glioblastoma has historically been thin. But results like these shift calculations, and some companies are beginning to pay attention.
Addressing the National Press Club in Canberra, Scolyer called on the research community to think beyond the silos of individual cancers, to design bolder trials, and to embed discovery into care. The words carried particular weight from a man who had just become, in his own words, patient zero on a frontier he and his colleagues were charting together.
Richard Scolyer was representing Australia at the world aquathon championships in Ibiza when May turned to June. He was fit, accomplished, a leading melanoma researcher at the institute bearing his field's name. Then came Poland, a hiking trip with his wife Katie Nicoll, and a morning that didn't feel quite right. A phone call to his mother in Tasmania. A seizure he wouldn't remember. A hospital. Tests. A diagnosis: glioblastoma IDH wild-type, the kind of brain cancer that kills most people within six to nine months, the kind considered incurable.
One of the first calls Nicoll made from that Polish hospital was to Georgina Long, Scolyer's co-medical director at Melanoma Institute Australia. Long described the moment with unflinching honesty: a physical pain unlike anything she'd known, grief for what her friend and colleague were about to endure, the thought of losing him. But that pain became fuel. She began researching glioblastoma, calling experts, hunting for clinical trials. What she found was a wasteland. The immunotherapy trials available for brain cancer could be counted on one hand.
Here was the crucial fact: Scolyer wasn't just a patient. He was a clinician and cancer researcher who understood the risks of what his team was about to attempt. With no established trials to enter, Long felt compelled to try something that hadn't been tried before—to treat his brain cancer the way they'd learned to treat melanoma. The melanoma institute had spent years perfecting immunotherapy, drugs that wake the immune system and point it at cancer. They'd seen those techniques transform survival rates for skin cancer. Why not the brain?
There was resistance. Some in the oncology community questioned the approach. Scolyer and Nicoll spent hours writing detailed letters explaining what he wanted to do and why. Then they moved forward. Scolyer received immunotherapy designed to activate his immune system against the cancer. His tumor's specific genetic code was sequenced and used to design a personalized vaccine targeting it. Twelve days later, he had surgery to remove the bulk of the tumor. The tissue was tested to see if the drugs had worked.
The results, Long said, were nothing short of phenomenal. They found a tenfold increase in immune cells within the tumor—cells that were activated against the cancer and bound to the drug. This proved something they'd already shown in melanoma but that conventional wisdom said shouldn't happen: the blood-brain barrier, long thought to block immunotherapy drugs from reaching brain tumors, was not the obstacle everyone believed. The drugs had gotten through. They had worked. In ten weeks, they'd generated discoveries that would normally take years.
But Scolyer and Long were careful not to overstate what this meant. One patient. Early scientific results. Too soon to know if phenomenal lab findings would translate to a better prognosis for Scolyer himself. The treatment he underwent won't be available to other patients—not yet, and perhaps not for years. Pharmaceutical companies have historically been reluctant to invest heavily in glioblastoma research. But early results like these change calculations. Some companies are beginning to pay attention.
At a National Press Club address in Canberra, Scolyer made a broader call. The cancer research field, he argued, needs to rethink its approach. Look beyond the boundaries of single cancers. Design better clinical trials. Embed research directly into patient care. We're not curing as many cancers as we could, he said. Think big. Be courageous. The words carried weight coming from a man who'd just done exactly that—who'd become, in his own phrase, patient zero in a frontier he and his colleagues were mapping in real time.
Citas Notables
Nothing had prepared me for that phone call from Katie in Poland. When I got that call, I got a physical pain like nothing I've ever experienced before.— Georgina Long, co-medical director
I can only do this because I'm a cancer researcher and clinician and so inherently understand the risks. This treatment may extend or shorten my life.— Richard Scolyer
La Conversación del Hearth Otra perspectiva de la historia
What made Long decide to pursue something so unconventional when Scolyer was diagnosed?
She looked for established paths first—clinical trials, standard protocols. When she found almost nothing, she faced a choice: accept the limits of what existed, or use what her team had learned from melanoma and try to adapt it. The grief was real, but it became a kind of permission to be bold.
Why does it matter that Scolyer is both researcher and patient?
He understands the science deeply enough to consent to genuine risk. He's not hoping for a miracle cure; he knows this might shorten his life as easily as extend it. That clarity allowed his team to move faster and take chances they couldn't take with someone who didn't grasp the uncertainties.
The tenfold increase in immune cells—what does that actually mean for his survival?
Honestly, they don't know yet. It's a signal that the approach works in principle, that the immune system can be activated against brain cancer. But one patient, early results, doesn't tell you whether he'll live longer. It tells you the theory was right. What happens next is still unwritten.
Why have pharmaceutical companies ignored glioblastoma until now?
It's a small market compared to other cancers, and it's been considered untreatable. Why invest billions in something everyone believes is hopeless? Early results like Scolyer's change that calculation. Suddenly there's a pathway worth exploring.
What's the broader implication of what they're doing?
They're arguing that cancer research has become too siloed—melanoma researchers stay in melanoma, brain cancer researchers stay in brain cancer. But the tools that work in one place might work elsewhere. You have to be willing to cross those lines and ask questions that seem naive from within your specialty.